205282(27.3)%Total net revenues
134,72136.4%Revenues for the quarter ended June 30, 2011 increased by $49.0 million, compared to the quarter ended June 30, 2010. The growth in revenues primarily reflects the increase in the number of patients being prescribed our products.
The table below summarizes research and development expense by major project and non-project components (dollars in thousands):Three Months EndedJune 30,20112010Percentage ChangeProject and non-project component:Cardiopulmonary
9,3058,5488.9%Total research and development expense
28,587(15.2)%Cardiopulmonary. The increase in expenses related to our cardiopulmonary projects for the quarter ended June 30, 2011 was attributable largely to increases in expenses related to our FREEDOM-C2 and FREEDOM-M clinical trials and our development of beraprost-MR.
Share-based compensation. The decrease in share-based compensation for the quarter ended June 30, 2011, compared to the same quarter in 2010, corresponded to a reduction in share-based compensation recognized in connection with our share tracking awards plans as a result of the decrease in our stock price.
The table below summarizes selling, general and administrative expense by major categories (in thousands):Three Months EndedJune 30,20112010Percentage ChangeCategory:General and administrative
18,75429.4%Sales and marketing
(17,484)(2,000)(774.2)%Total selling, general and administrative expense
29,654(19.6)%General and administrative. The increase in general and administr
|SOURCE United Therapeutics Corporation|
Copyright©2010 PR Newswire.
All rights reserved